Clinical Trials: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Sponsor and Collaborators

ChemGenex Pharmaceuticals

Contact

Eric Humphriss

800-877-3009 ext 112

[email protected]

Adam Craig, MD

800-877-3009 ext 121

[email protected]

Principal Investigator

Jorge Cortes, MD, Univ. of Texas M.D. Anderson Cancer Center

Andreas Hochhaus, MD, Prof Dr

Mannheim der Universitat Heidelberg

ClinicalTrials.gov Identifier

NCT00375219